A multicenter double blind placebo controlled adaptive Phase 3 trial of POL-103A polyvalent melanoma vaccine in post-resection melanoma patients with a high risk of recurrence
|Effective start/end date||1/1/12 → 12/31/21|
- POLYNOMA LLC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.